Tags

Type your tag names separated by a space and hit enter

Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia / lymphoma.
Cancer Sci 2013; 104(5):647-50CS

Abstract

We report an adult T-cell leukemia/lymphoma patient suffering from Stevens-Johnson Syndrome (SJS) during mogamulizumab (humanized anti-CCR4 monoclonal antibody) treatment. There was a durable significant reduction of the CD4(+) CD25(high) FOXP3(+) regulatory T (Treg) cell subset in the patient's PBMC, and the affected inflamed skin almost completely lacked FOXP3-positive cells. This implies an association between reduction of the Treg subset by mogamulizimab and occurrence of SJS. The present case should contribute not only to our understanding of human pathology resulting from therapeutic depletion of Treg cells, but also alert us to the possibility of immune-related severe adverse events such as SJS when using mogamulizumab. We are currently conducting a clinical trial of mogamulizumab for CCR4-negative solid cancers (UMIN000010050), specifically aiming to deplete Treg cells.

Authors+Show Affiliations

Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. itakashi@med.nagoya-cu.ac.jpNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23360455

Citation

Ishida, Takashi, et al. "Stevens-Johnson Syndrome Associated With Mogamulizumab Treatment of Adult T-cell Leukemia / Lymphoma." Cancer Science, vol. 104, no. 5, 2013, pp. 647-50.
Ishida T, Ito A, Sato F, et al. Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia / lymphoma. Cancer Sci. 2013;104(5):647-50.
Ishida, T., Ito, A., Sato, F., Kusumoto, S., Iida, S., Inagaki, H., ... Ueda, R. (2013). Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia / lymphoma. Cancer Science, 104(5), pp. 647-50. doi:10.1111/cas.12116.
Ishida T, et al. Stevens-Johnson Syndrome Associated With Mogamulizumab Treatment of Adult T-cell Leukemia / Lymphoma. Cancer Sci. 2013;104(5):647-50. PubMed PMID: 23360455.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia / lymphoma. AU - Ishida,Takashi, AU - Ito,Asahi, AU - Sato,Fumihiko, AU - Kusumoto,Shigeru, AU - Iida,Shinsuke, AU - Inagaki,Hiroshi, AU - Morita,Akimichi, AU - Akinaga,Shiro, AU - Ueda,Ryuzo, Y1 - 2013/03/10/ PY - 2012/12/25/received PY - 2013/01/21/revised PY - 2013/01/23/accepted PY - 2013/1/31/entrez PY - 2013/1/31/pubmed PY - 2013/9/14/medline SP - 647 EP - 50 JF - Cancer science JO - Cancer Sci. VL - 104 IS - 5 N2 - We report an adult T-cell leukemia/lymphoma patient suffering from Stevens-Johnson Syndrome (SJS) during mogamulizumab (humanized anti-CCR4 monoclonal antibody) treatment. There was a durable significant reduction of the CD4(+) CD25(high) FOXP3(+) regulatory T (Treg) cell subset in the patient's PBMC, and the affected inflamed skin almost completely lacked FOXP3-positive cells. This implies an association between reduction of the Treg subset by mogamulizimab and occurrence of SJS. The present case should contribute not only to our understanding of human pathology resulting from therapeutic depletion of Treg cells, but also alert us to the possibility of immune-related severe adverse events such as SJS when using mogamulizumab. We are currently conducting a clinical trial of mogamulizumab for CCR4-negative solid cancers (UMIN000010050), specifically aiming to deplete Treg cells. SN - 1349-7006 UR - https://www.unboundmedicine.com/medline/citation/23360455/Stevens_Johnson_Syndrome_associated_with_mogamulizumab_treatment_of_adult_T_cell_leukemia_/_lymphoma_ L2 - https://doi.org/10.1111/cas.12116 DB - PRIME DP - Unbound Medicine ER -